Chiome Bioscience Inc.

As of June 30, 2026, Chiome Bioscience Inc. carries a market capitalization of 6.23B, placing it among publicly traded companies globally. Its enterprise value stands at 4.93B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Chiome Bioscience Inc.'s next confirmed earnings release is scheduled for November 10, 2026.

As of June 30, 2026, Chiome Bioscience Inc. has 78.92M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Chiome Bioscience Inc. maintains a current ratio of 6.07, meaning it holds 6.1x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Chiome Bioscience Inc.'s stock has declined approximately 33.09% over the past 52 weeks. The 50-day moving average sits at 90.66, while the 200-day moving average is 93.86.

As of June 30, 2026, Chiome Bioscience Inc. holds 1.37B in cash and equivalents against 67.50M in total debt, resulting in a net debt position of -1.30B. Total book value stands at 1.57B, with working capital of 1.45B providing operational flexibility.

Chiome Bioscience Inc.'s most recent stock split took place on March 27, 2014 with a 1:2 split ratio.